Ultrahuman Revenue, Valuation, Funding & Investors

Ultrahuman is valued at $365M as of September 2026.

Last Ultrahuman valuation

$365M

Series C · Sep 2026

Last Ultrahuman funding round

$65M

Series C · Sep 2026

Ultrahuman revenue

$64M

Series B · Mar 2024

Key investors in Ultrahuman

  • Blume Ventures
  • Nexus Venture Partners
  • Deepinder Goyal
  • Steadview Capital
  • Alpha Wave Incubation
  • Qualcomm Ventures

Ultrahuman Overview

About Ultrahuman

Ultrahuman is a multi-location health technology company with bases in London, Abu Dhabi, and Bengaluru, producing wearable devices for metabolic and longevity monitoring. It manufactures the Ring Air smart ring for continuous heart rate variability and movement tracking, the M1 continuous glucose monitor for real-time blood sugar insights, and the Home environmental sensor for air quality and sleep optimization. The firm also offers at-home blood testing kits through its Blood Vision service. Ultrahuman targets athletes and wellness enthusiasts globally, integrating with Apple Health and Google Fit. Founded in 2020, it has raised significant venture funding from investors like Blume Ventures.


Founded

2019

HQ

IndiaBangalore

Status

Privately held

Customer focus

B2C

Revenue model

Product sales

Revenue

$64M (Mar 2024)

Valuation

$365M (Sep 2026)

Ultrahuman Valuation

Ultrahuman is currently valued at $365M, based on its Series C in September 2026.

The $65M round was led by Qualcomm Ventures, with participation from Deepinder Goyal, Alteria Capital, Incred Wealth, Steadview Capital, Labcorp and 4 other investors.

Ultrahuman's valuation has grown 2.9x from $125M at its Series B in March 2024 to $365M in September 2026, across 2 priced rounds.

Ultrahuman valuation by funding round

Revenue multiple
Ultrahuman valuation by funding round
DateStageValuationRevenue Multiple
Sep 2026Series C$365M-
Mar 2024Series B$125M2.0x

Ultrahuman Revenue

Ultrahuman's latest recorded revenue is $64M, as of its Series B in March 2024. At a $125M valuation, that implies a 2.0x revenue multiple.

Ultrahuman revenue by funding round

Ultrahuman revenue and valuation multiple by funding round
DateRevenue *ValuationRevenue MultipleStage
Mar 2024$64M$125M2.0xSeries B

* Revenue (or ARR) figures are the values recorded alongside each funding round. Typically run-rate revenue at the time of the deal, or a reported LTM (last 12 months) revenue.

Ultrahuman Funding History

Ultrahuman has raised a total of $159M across 5 funding rounds.

Ultrahuman's first fundraising round was a $8M Series A in December 2020. The most recent completed round was a $65M Series C in September 2026.

Ultrahuman funding rounds

Ultrahuman funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Sep 2026Series CQualcomm Ventures (lead); Deepinder Goyal; Alteria Capital; Incred Wealth; Steadview Capital; Labcorp; Blume Ventures; krypton fund; Alpha Wave Global; Nexus Venture Partners$65M$365MQualcomm Ventures led Ultrahuman’s $70 million Series C financing in September 2026, with participation from Alpha Wave Global, Labcorp, Blume Ventures, Nexus Venture Partners, and Alteria Capital. The round included $65 million in primary equity and $5 million in debt, and valued Ultrahuman at $365 million. The company said the capital will be used to expand research and development across sensing, AI, miniaturised electronics, and health algorithms, while increasing investment in clinical science and large-scale research. The transaction comes as Ultrahuman pushes beyond sleep and health tracking toward a smarter ring platform capable of running software on-device and supporting AI interactions and games. Ultrahuman is a Bengaluru-based health intelligence company best known for its smart rings and related metabolic-health products. The company has positioned its devices around wearable health tracking and is expanding into more advanced on-device computing and health software.
Feb 2026Series C-$44M--
Mar 2024Series BBlume Ventures (lead); Nexus Venture Partners (lead); Steadview Capital (lead); Deepinder Goyal; Alpha Wave Incubation$25M$125MUltrahuman, a Bengaluru-based wearable tech company specializing in smart rings and health tracking devices like continuous glucose monitoring, closed a $35 million Series B funding round in March 2024, comprising $25 million in equity and $10 million in debt. The round was led by Blume Ventures and Nexus Venture Partners, with participation from Steadview Capital, Alpha Wave (also referred to as Alpha Wave Global or Incubation), and Zomato co-founder Deepinder Goyal. This funding valued the company at $125 million, as reported in coverage of the deal. The proceeds are earmarked for enhancing manufacturing capacity, including the UltraFactory facility capable of supporting $200 million in annual revenue, and deepening research in health tracking, such as clinical trials validating features like Metabolic Score. At the time of the round, Ultrahuman positioned itself as the second-largest smart ring maker globally behind Oura, aiming to overtake the leader within 12-15 months through aggressive growth. Financial traction included FY23 revenue of Rs 24 crore (up from Rs 2 crore in FY21), with equal contributions from retail/D2C (60%) and e-commerce/B2B. Post-round developments include talks for additional $100-120 million at $500-550 million valuation (unconfirmed) and later ₹100 crore venture debt from Alteria Capital, plus FY25 revenue of $64 million and $8.2 million net profit.
Aug 2021Series BGaurav Munjal; Gunjan Patidar; Deepinder Goyal; Roman Saini; Blume Ventures; iSeed; Revant Bhate; Alpha Wave Incubation; Mohit Gupta; Nexus Venture Partners; Sandeep Singhal; Kunal Shah$18M-Ultrahuman is a Bengaluru-based healthtech company offering a wearable device that tracks glucose biomarkers to help users optimize exercise and nutrition for metabolic fitness. The platform, branded as Ultrahuman Cyborg, analyzes data from a skin patch extracting glucose from interstitial fluid via a companion app. Founded by Mohit Kumar and Vatsal Singhal, previously co-founders of Runnr which merged with Zomato, the company targets the global metabolic health crisis affecting over 1 billion people contributing to 85% of chronic diseases. Ultrahuman raised $17.5 million in its Series A (or Series B per some reports) funding round announced around August 17, 2021, bringing total funding to $25 million. Investors included Alpha Wave Incubation (AWI), Steadview Capital, Nexus Venture Partners, Blume Ventures, iSeed fund, and angels such as Deepinder Goyal, Gaurav Munjal, Kunal Shah, Gunjan Patidar, Mohit Gupta, Revant Bhate, Roman Saini, and Sandeep Singhal. The funds support geographical expansion, team strengthening, life sciences research, and improvements to biomarker technology including glucose tracking. At the time, Ultrahuman reported thousands on the waitlist for its closed beta glucose tracker subscription with 60% week-over-week sign-up growth, planning wider availability in early 2022.
Dec 2020Series AMars Shot Ventures; Rainmatter Capital; ICE.vc; Blume Ventures; Nexus Venture Partners$8M--

Who has invested in Ultrahuman?

22 investors have backed Ultrahuman across its funding rounds, including Blume Ventures, Nexus Venture Partners, Deepinder Goyal, Steadview Capital, Alpha Wave Incubation and Qualcomm Ventures.

Lead investors include Qualcomm Ventures, Blume Ventures, Nexus Venture Partners and Steadview Capital.


Ultrahuman Investors

Investors in Ultrahuman by funding rounds participated
InvestorHQRoundsRoleFirst check
Blume VenturesIndiaMumbai4LeadDec 2020
Nexus Venture PartnersUnited StatesSan Francisco, CA4LeadDec 2020
Deepinder GoyalIndiaNew Delhi3ParticipantAug 2021
Steadview CapitalUnited KingdomLondon2LeadMar 2024
Alpha Wave IncubationUnited StatesNew York City, NY2ParticipantAug 2021
Qualcomm VenturesUnited StatesSan Diego, CA1LeadSep 2026
Gaurav MunjalIndiaIndia1ParticipantAug 2021
Gunjan PatidarIndiaNew Delhi1ParticipantAug 2021
Mars Shot VenturesIndiaBangalore1ParticipantDec 2020
Roman SainiIndiaBangalore1ParticipantAug 2021
Alteria CapitalIndiaMumbai1ParticipantSep 2026
Incred WealthIndiaMumbai1ParticipantSep 2026
LabcorpUnited StatesUnited States1ParticipantSep 2026

This data is available for Pro users. Sign up to see all 22 Ultrahuman investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by Ultrahuman

Ultrahuman has acquired 2 companies to date.

Last acquisition by Ultrahuman was on August 15th 2025. Ultrahuman acquired viO HealthTech for undisclosed valuation.


Latest Acquisitions by Ultrahuman

viO HealthTech
Lazy Co.
Description
-
Lazy Co. is a San Francisco-headquartered startup building an AI-powered wearable device that enables gesture-based control of smartphones. The product aims to replace traditional touch interactions with intuitive hand movements detected by advanced sensors and machine learning algorithms.
HQ CountryUnited StatesIndia
HQ City
Old Saybrook, CT
Bangalore
Deal Date15 Aug 202512 Apr 2022
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Ultrahuman acquisitions and their M&A valuation multiples.

Start Free Trial

Ultrahuman Competitors

Ultrahuman competitors include listed companies like TALI Digital and Sphere, and private ones like Biopeak, Found, Calibrate and Cult.fit.

Public and private companies comparable to Ultrahuman
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
BiopeakIndiaBangalorePrivate$2M-$250M125.0x
FoundUnited StatesSan Francisco, CAPrivate--$600M-
CalibrateUnited StatesNew York City, NYPrivate$21M-$1.3B61.9x
Cult.fitIndiaBangalorePrivate$74M-$1.5B-
TALI DigitalAustraliaAustraliaPublicly listed$166K($2M)$3M-
SphereSouth KoreaSouth KoreaPublicly listed$70M$6M$813M6.9x

Ultrahuman Public Comps

Ultrahuman is still privately-owned, but its public comps include Sportsoul, Escalade, H100 Group, Nyxoah, Weight Watchers, Grupo Sports World, Viva Leisure, Oneview Healthcare, Kooth and Shua Fitness.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Sportsoul$68M($4M)4.8x4.5x(88.7x)-
Escalade$240M$24M1.1x1.1x11.2x8.7x
H100 Group$1M($36M)150.7x-(5.1x)-
Nyxoah$12M($97M)9.5x3.2x(1.1x)(1.4x)
Weight Watchers$786M($198M)0.6x0.7x(2.4x)4.0x
Grupo Sports World$127M$49M0.9x1.1x2.4x3.1x
Viva Leisure$167M$78M2.3x2.2x4.9x9.0x
Oneview Healthcare$14M($12M)7.1x7.1x(8.2x)(11.3x)

This data is available for Pro users. Sign up to see all Ultrahuman competitors and their valuation data.

Start Free Trial

Common questions about Ultrahuman

When was Ultrahuman founded?Ultrahuman was founded in 2019.
Where is Ultrahuman headquartered?Ultrahuman is headquartered in Bangalore, India.
Is Ultrahuman publicly listed?No, Ultrahuman is a private, VC-backed company.
What is Ultrahuman's valuation?Ultrahuman was last valued at $365M in its Series C in September 2026.
How much funding has Ultrahuman raised?Ultrahuman has raised $159M across 5 funding rounds.
What was Ultrahuman's last funding round?Ultrahuman's last funding round was a $65M Series C in September 2026, led by Qualcomm Ventures.
Who are Ultrahuman's investors?Ultrahuman's investors include Blume Ventures, Nexus Venture Partners, Deepinder Goyal, Steadview Capital, Alpha Wave Incubation, Qualcomm Ventures, Gaurav Munjal, Gunjan Patidar, Mars Shot Ventures, Roman Saini and 12 others.
What is Ultrahuman's revenue?Ultrahuman's latest recorded revenue is $64M (March 2024).
What is Ultrahuman's revenue multiple?Ultrahuman's latest valuation implies a 2.0x revenue multiple ($125M valuation on $64M of revenue).
Which companies are comparable to Ultrahuman?Companies comparable to Ultrahuman include Biopeak, Found, Calibrate, Cult.fit, TALI Digital and Sphere.
How many companies has Ultrahuman acquired?Ultrahuman has acquired 2 companies, including viO HealthTech and Lazy Co..

See companies similar to Ultrahuman

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial